| Original language | English |
|---|---|
| Article number | 102813 |
| Number of pages | 8 |
| Journal | NeuroImage: Clinical |
| Volume | 32 |
| DOIs | |
| Publication status | Published - 2021 |
| Externally published | Yes |
Austrian Fields of Science 2012
- 302054 Nuclear medicine
Keywords
- (+)-[C]-PHNO
- Dopamine
- Glucose
- Psychosis
- BASE-LINE
- TOLERANCE
- METABOLIC DYSREGULATION
- D-2 RECEPTORS
- (+)-[C-11]-PHNO
- INSULIN
- POSITRON-EMISSION-TOMOGRAPHY
- PHARMACOLOGY
- MORTALITY GAP
- ENDOGENOUS DOPAMINE
- ASSOCIATION
Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver
}
In: NeuroImage: Clinical, Vol. 32, 102813, 2021.
Publications: Contribution to journal › Article › Peer Reviewed
TY - JOUR
T1 - Disrupted relationship between blood glucose and brain dopamine D2/3 receptor binding in patients with first-episode schizophrenia
AU - Sauerzopf, U.
AU - Weidenauer, A.
AU - Dajic, I.
AU - Bauer, M.
AU - Bartova, L.
AU - Meyer, B.
AU - Nics, L.
AU - Philippe, C.
AU - Pfaff, S.
AU - Pichler, V.
AU - Mitterhauser, M.
AU - Wadsak, W.
AU - Hacker, M.
AU - Kasper, S.
AU - Lanzenberger, R.
AU - Pezawas, L.
AU - Praschak-Rieder, N.
AU - Willeit, M.
N1 - Funding Information: This project was funded by the Vienna Science and Technology Fund (WWTF, Grant number: CS15-033), the Austrian Science Fund (FWF, Grant number: P23585-B09), the Anniversary Fund of the Austrian National Bank (Grant number. 16723), the Medical Scientific Fund of the Mayor of the City of Vienna (Grant number 15189), all granted to M.W. Funding Information: Without relevance to this work, M. Willeit declares to having received speaker honoraria and consulting fees from Janssen-Cilag Pharma GmbH, Austria. Without relevance to this work, W. Wadsak declares to havingreceived speaker honoraria from GE Healthcare, research grants from IpsenPharma, Eckert-Ziegler AG, Scintomics and ITG. WW is a part time eployee ofCBmed Ltd (Center for Biomarker Research in Medicine, Graz, Austria). and is a member of advisory boards of Amgen, Chieri and Sanofi-Aventis. M. Hacker received consulting fees and/or honoraria from Bayer Healthcare BMS, Eli Lilly, EZAG, GE Healthcare, Ipsen, ITM, Janssen, Roche, Siemens Healthineers. R. Lanzenberger received travel grants and/or conference speaker honoraria within the last three years from Bruker BioSpin MR, Heel, and support from Siemens Healthcare regarding clinical research using PET/MR. He is a shareholder of the start-up company BM Health GmbH since 2019. S. Kasper received grants/research support, consulting fees and/or honoraria within the last three years from Angelini, AOP OrphanPharmaceuticals AG, Celegne GmbH, Eli Lilly, Janssen-Cilag Pharma GmbH, KRKA-Pharma, Lundbeck A/S, Mundipharma, Neuraxpharm, Pfizer, Sanofi, Schwabe, Servier, Shire, Sumitomo Dainippon Pharma Co. Ltd. and Takeda. U. Sauerzopf, A. Weidenauer, I. Dajic, M. Bauer, L. Bartova, B. Meyer, L. Nics, C. Philippe, S. Pfaff, V. Pichler, M. Mitterhauser, L. Pezawas and N. Praschak-Rieder have no conflict of interest to declare. Publisher Copyright: © 2021 The Author(s) Copyright: Copyright 2021 Elsevier B.V., All rights reserved.
PY - 2021
Y1 - 2021
KW - (+)-[C]-PHNO
KW - Dopamine
KW - Glucose
KW - Psychosis
KW - BASE-LINE
KW - TOLERANCE
KW - METABOLIC DYSREGULATION
KW - D-2 RECEPTORS
KW - (+)-[C-11]-PHNO
KW - INSULIN
KW - POSITRON-EMISSION-TOMOGRAPHY
KW - PHARMACOLOGY
KW - MORTALITY GAP
KW - ENDOGENOUS DOPAMINE
KW - ASSOCIATION
UR - http://www.scopus.com/inward/record.url?scp=85114996749&partnerID=8YFLogxK
U2 - 10.1016/j.nicl.2021.102813
DO - 10.1016/j.nicl.2021.102813
M3 - Article
AN - SCOPUS:85114996749
SN - 2213-1582
VL - 32
JO - NeuroImage: Clinical
JF - NeuroImage: Clinical
M1 - 102813
ER -